BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany.

加利福尼亚州伯克利和德国美因茨，2024年3月12日（环球通讯社）--美因茨生物医学公司（NASDAQ:MYNZ）（“美因茨生物医学”或“公司”）是早期癌症检测分子遗传学诊断解决方案的领军者，很自豪地宣布将参加3月16日和17日在德国费尔巴赫举行的2024年第39届UDH大会。

One of the main focus topics for this year’s event, organized by the German Complementary Medicine Association (Union Deutscher Heilpraktiker, Landesverband Baden-Württemberg), is the gut and its significance in the manifestation of diseases. Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.

今年由德国补充医学协会（Union Deutscher Heilpraktiker，Landesverband Baden-Württemberg）组织的活动的主要焦点之一是肠道及其在疾病表现中的意义。美因茨生物医学公司在UDH大会上的展示突显了该公司致力于将最新的科学研究与广泛的医疗保健实践联系起来。

Mainz Biomed’s engagement reflects a deep respect for the diverse methodologies within the healthcare community, emphasizing the commitment to contributing evidence-based, innovative solutions like ColoAlert®. ColoAlert®, Mainz Biomed’s flagship product, is a testament to the Company’s mission, providing a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit.

美因茨生物医学公司的参与反映了对医疗保健界多种方法的深切尊重，强调致力于提供基于证据的创新解决方案，如ColoAlert®。美因茨生物医学公司的旗舰产品ColoAlert®证明了该公司的使命，它提供了一种高度准确、易于使用的家庭结直肠癌（CRC）筛查试剂盒。

Its advanced tumor DNA analysis technology significantly improves early detection rates, a crucial factor in effective CRC management. By presenting ColoAlert® at the UDH Congress, Mainz Biomed highlights the role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies, demonstrating the synergy between technological innovation and patient-centric care.

其先进的肿瘤DNA分析技术显着提高了早期检出率，这是有效CRC管理的关键因素。通过在UDH大会上介绍ColoAlert®，Mainz Biomed强调了尖端分子诊断在增强综合健康战略中的作用，展示了技术创新与以患者为中心的护理之间的协同作用。

This initiative is part of Mainz Biomed’s broader strategy to foster collaboration and knowledge exchange across the health sector. The Company aims to elevate the standard of care and advocate for the health and well-being of individuals through science-bac.

这一举措是美因茨生物医学公司促进卫生部门合作和知识交流的更广泛战略的一部分。该公司旨在通过科学bac提高护理标准，倡导个人的健康和福祉。